Ушбу иш иқтибос қилган ишлар

52 та иш

Иш: Genetic engineering in oncology based on CRISPR-Cas9 technology

1. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

   Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

   Мақола20174 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.020478

2. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

   Wanghong Hu, Zhenguo Zi, Yanling Jin +5

   Мақола20183 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.020506

3. Delivering CRISPR: a review of the challenges and approaches

   Christopher A. Lino, Jason C. Harper, James P. Carney +1

   Шарҳ мақола20183 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.051686

4. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

   Zhenguang Wang, Na Li, Kaichao Feng +14

   Мақола20213 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102893

5. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

   Na Tang, Chen Cheng, Xingying Zhang +6

   Мақола20203 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.296864

6. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

   Bryan D. Choi, Xiaoling Yu, Ana P. Castaño +14

   Мақола20192 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.020532

7. Nobel Prize 2020 in Chemistry honors CRISPR: a tool for rewriting the code of life

   Lukas Westermann, Björn Neubauer, Michael Köttgen

   Таҳририят мақоласи20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.051744

8. The Potential Revolution of Cancer Treatment with CRISPR Technology

   Dimitrios Stefanoudakis, Nikhita Kathuria‐Prakash, Alexander W. Sun +10

   Шарҳ мақола20232 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.082292

9. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing

   Muhammad Naeem, Saman Majeed, Mubasher Zahir Hoque +1

   Шарҳ мақола20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.452270

10. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

    Dana Stenger, Tanja A. Stief, Theresa Kaeuferle +12

    Мақола20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.475820

11. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735602

12. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735603

13. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735604

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735605

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735606

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735607

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735608

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735609

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735610

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735611

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735612

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735613

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735614

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735615

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.735616